Information:
Fel:
ID
34157
Beskrivning
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01363986
Länk
https://clinicaltrials.gov/show/NCT01363986
Nyckelord
Versioner (1)
- 2019-01-14 2019-01-14 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
14 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT01363986
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
diagnosis of breast carcinoma with her-2 overexpression
boolean
ID.3
Item
at least one measurable brain metastasis
boolean
ID.4
Item
patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option
boolean
ID.5
Item
performance status (who) </=2
boolean
ID.6
Item
life expectancy >/=3 months
boolean
ID.7
Item
presence of neoplastic meningitis
boolean
ID.8
Item
any prior radiotherapy to the brain
boolean
ID.9
Item
patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option
boolean
ID.10
Item
previous neoplasms, other than breast carcinoma, within 5 years since enrolment
boolean